Pfizer 2010 Annual Report Download - page 117

Download and view the complete annual report

Please find page 117 of the 2010 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 120

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120

Quarterly Consolidated Financial Data (Unaudited)
Pfizer Inc. and Subsidiary Companies
QUARTER
(MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA) FIRST SECOND THIRD FOURTH
2010
Revenues $16,750 $ 17,327 $16,171 $ 17,561
Costs and expenses(a) 12,791 12,467 14,232 15,558
Acquisition-related in-process research and development charges 74 — — 51
Restructuring charges and certain acquisition-related costs(b) 706 886 499 1,123
Income from continuing operations before provision for taxes on income 3,179 3,974 1,440 829
Provision/(benefit) for taxes on income(c) 1,146 1,488 564 (2,074)
Income from continuing operations 2,033 2,486 876 2,903
Discontinued operations—net of tax 2 (1) (5) (5)
Net income before allocation to noncontrolling interests 2,035 2,485 871 2,898
Less: Net income attributable to noncontrolling interests 9105 8
Net income attributable to Pfizer Inc. $ 2,026 $ 2,475 $ 866 $ 2,890
Earnings per common share—basic:
Income from continuing operations attributable to Pfizer Inc. common
shareholders $ 0.25 $ 0.31 $ 0.11 $ 0.36
Discontinued operations—net of tax ————
Net income attributable to Pfizer Inc. common shareholders $ 0.25 $ 0.31 $ 0.11 $ 0.36
Earnings per common share—diluted:
Income from continuing operations attributable to Pfizer Inc. common
shareholders $ 0.25 $ 0.31 $ 0.11 $ 0.36
Discontinued operations—net of tax ————
Net income attributable to Pfizer Inc. common shareholders $ 0.25 $ 0.31 $ 0.11 $ 0.36
Cash dividends paid per common share $ 0.18 $ 0.18 $ 0.18 0.18
Stock prices
High $ 20.36 $ 17.39 $ 17.50 $ 17.90
Low $ 16.80 $ 14.00 $ 14.14 $ 16.25
(a) The increase in costs and expenses in the fourth quarter of 2010, compared to the third quarter of 2010, is due to higher Cost of sales, Selling,
informational and administrative expenses, and Amortization of intangible assets, partially offset by lower charges recorded in Other deductions—net.
(b) The increase in the fourth quarter of 2010, compared to the third quarter of 2010, is due to higher integration charges and restructuring costs primarily
related to our acquisition of Wyeth.
(c) The fourth quarter of 2010 includes a $2.0 billion tax benefit recorded as a result of a settlement of certain tax audits covering the years 2002 – 2005.
Basic and diluted EPS are computed independently for each of the periods presented. Accordingly, the sum of the quarterly EPS
amounts may not agree to the total for the year.
As of January 31, 2011, there were 232,567 holders of record of our common stock (New York Stock Exchange symbol PFE).
2010 Financial Report 115